Last reviewed · How we verify
A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC
This is a two-arm, randomized, double-blinded, multicenter phase II/III clinical study to evaluate the safety and clinical efficacy of SHR-1701 or placebo in combination with BP102 (biosimilar to bevacizumab) and XELOX in first-line treatment of patients with mCRC.
Details
| Lead sponsor | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
|---|---|
| Phase | PHASE2, PHASE3 |
| Status | TERMINATED |
| Enrolment | 62 |
| Start date | Tue Jun 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Wed Apr 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Metastatic Colorectal Cancer (mCRC)
Interventions
- SHR-1701、 BP102 、XELOX
- SHR-1701、 BP102 、XELOX
- placebo、 BP102、 XELOX
Countries
China